AUPH PEER ANALYSIS

Aurinia Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

AUPHAurinia Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
AUPHIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
AUPH+108.4%TLX-29.5%MSB+27.6%CSL-48.2%
Year-to-Date (YTD)
AUPH-2.1%TLX+50.7%MSB-24.3%CSL-28.5%

Key Metric Comparison

P/E

Lower is better
AUPH7.20TLXMSBCSL29.44Median 17.91

ROE

Higher is better
AUPH65.0%TLX-1.8%MSB-11.3%CSL7.7%Median -47.5%

Net Margin

Higher is better
AUPH100.0%TLX-0.9%MSB-115.3%CSL9.2%Median -125.7%

Revenue Growth

Higher is better
AUPH20.6%TLX56.3%MSB410.4%CSL4.8%Median 5.1%

All Metrics

Valuation
MetricAUPHTLXMSBCSLInd. Median
P/E7.2029.4417.91
P/B3.796.372.203.51
EV/EBITDA11.36120.1410.2114.82
P/S7.203.2431.612.6210.89
Financial Health
MetricAUPHTLXMSBCSLInd. Median
Current Ratio5.551.432.575.90
Debt/Equity12.1%112.3%67.4%10.9%
NetDebt/EBITDA-1.9213.132.221.15
Profitability
MetricAUPHTLXMSBCSLInd. Median
Net Margin100.0%-0.9%-115.3%9.2%-125.7%
ROE65.0%-1.8%-11.3%7.7%-47.5%
ROA48.5%-0.7%-8.6%3.8%-35.8%
EBITDA Margin54.2%3.0%-76.6%32.8%-105.8%
Growth + Dividend
MetricAUPHTLXMSBCSLInd. Median
Rev. Growth20.6%56.3%410.4%4.8%5.1%
NI Growth648.4%-39.4%12.1%
Div. Yield0.0%2.5%0.2%
Payout0.0%103.1%0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on AUPH

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.